Clock (Image 01)
Opill Tablet
Product Images NDC 67296-1938
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Opill (NDC 67296-1938). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Condom (Image 02)
Female-outline (Image 03)
An anatomical diagram of the female reproductive system showing the uterus and ovaries. The illustration highlights the mechanism of action of Opill, indicating that it prevents the release of an egg from the ovary, may not prevent ovulation in all cycles, and thickens cervical mucus to block sperm from reaching the egg. It also notes that Opill works from 2 days after beginning to take it.*
Tier-one (Image 04)
An instructional diagram showing four contraceptive methods: Implant, Female Sterilization, Vasectomy, and IUD. Each method is illustrated with a simple line drawing depicting anatomical areas and devices relevant to the method.*
Tier-two (Image 05)
An instructional illustration showing four contraceptive product types: an injectable syringe and vial labeled 'Injectable,' a blister pack of tablets labeled 'Pill,' a square adhesive labeled 'Patch,' and a circular device labeled 'Ring.' The image visually differentiates common contraceptive methods.*
Tiers (Image 06)
An instructional illustration showing various contraceptive methods. Depicted are male condom, female condom, withdrawal, diaphragm, fertility awareness based methods with calendar and thermometer, spermicides, and a sponge, each represented by simple icons or drawings.*
Opill-pdp (Image 07)
Opill Norgestrel tablets 0.075 mg Daily Oral Contraceptive tablet packaging label by Redpharm Drug. The label indicates a 28 tablet supply, representing a 28-day regimen. It mentions full prescription strength and states that this product is FDA approved. The packaging includes dosing instructions to take one tablet daily and warns not to use as an emergency contraceptive. Manufactured for Laboratoire HRA Pharma and distributed by PMI Branded Pharmaceuticals, Inc.*
Opill-dfl-one (Image 08)
Drug Facts for Opill tablets, containing 0.075 mg norgestrel as the active ingredient, used as a daily oral contraceptive. The label includes warnings about allergies, use restrictions, sexually transmitted disease alerts, when to ask a doctor, side effects, and directions for proper use. It advises taking one tablet daily at the same time and details precautions and when to seek medical help.*
Opill-dfl-two (Image 09)
Drug Facts panel continuing directions for use, warnings, other information, inactive ingredients, and contact information for Opill, a norgestrel oral tablet. It details instructions on daily tablet use, missed doses, condom use guidance, storage conditions, and a customer service phone number.*
Reminder-card-front (Image 10)
This text panel reminds users to take one tablet of Opill (norgestrel 0.075 mg oral tablet) at the same time every day without breaks. It advises continuing even if menstrual changes occur and using backup contraception for two days if a tablet is late or missed. It references the Drug Facts and consumer information leaflet for details.*
Reminder-card-back (Image 11)
Label for Opill norgestrel tablets 0.075 mg oral dosage form. The label includes a reminder feature to note the time to take the pill and provides tips for daily adherence such as pairing with a daily task, keeping the pack visible, placing reminders in common areas, and setting an alarm on a smartphone. The labeler is Redpharm Drug.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
